Development of Mouse Models and Gene Therapy for Gaucher Disease
Gaucher disease (GD) patients cannot metabolize glycosphingolipids properly due to deficiency of the enzyme glucosylceramidase (GCase). The lack of animal model for GD has hindered comprehensive investigation of disease mechanisms and also the development of curative treatment strategies such as hematopoietic stem cell (HSC) targeted gene therapy. Previous GCase deficient mice have either been let
